HIKALNSEHikal Limited· PharmaceuticalsLowNeutral
Announced Mon, 13 Apr · 16:33 IST

The Exchange had sought clarification from Hikal Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is enclosed.

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.1%1-day move
₹182.02
prior close
₹185.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+0.6+0.6+0.8+4.1+5.4+2.8+2.7+3.9-0.0+17.0+11.7+2.3+31.9
Up moveDown movePending
AI summary

NSE had sought clarification from Hikal Limited regarding discrepancies in the company's XBRL filing for Q2 FY2025 (quarter ended September 30, 2025). The company admitted that in its XBRL submission made on November 13, 2025, the EPS was incorrectly tagged under 'Earnings per equity share for discontinued operations' instead of 'Earnings per equity share for continuing operations'. The company clarified that the EPS was correctly disclosed in the PDF filing. The corrected EPS for the quarter is Rs. (2.81) and for year to date is Rs. (4.65) - both negative, indicating losses. The company regretted this inadvertent error and requested NSE to update its records.

Likely market impact

This is a minor administrative correction - the actual financial numbers were correctly reported in the PDF filing, only the XBRL categorization was wrong. The negative EPS reflects operational losses but was not a new development. Shareholders need not be concerned as this was an inadvertent tagging error, not a financial misstatement.